Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity - Additional Information (Details)

v3.24.1
Stockholders' Equity - Additional Information (Details) - USD ($)
 1 Months Ended 2 Months Ended 12 Months Ended
Nov. 17, 2023
Nov. 15, 2023
Nov. 13, 2023
Nov. 09, 2023
May 25, 2023
Apr. 27, 2023
Aug. 03, 2022
Aug. 01, 2022
May 31, 2022
Jan. 31, 2022
Nov. 30, 2023
Feb. 28, 2022
Dec. 31, 2023
Dec. 31, 2022
Sep. 01, 2023
Subsidiary or Equity Method Investee [Line Items]                              
Common stock, shares authorized               70,000,000         70,000,000 70,000,000  
Preferred stock, shares authorized               30,000,000         30,000,000 30,000,000  
Common stock, par value                         $ 0.0001 $ 0.0001  
Preferred stock, shares issued                         0 0  
Preferred stock, par value                         $ 0.0001  
Common stock, shares issued                         16,986,254 10,955,904  
Common stock per share                       $ 9      
Gross proceeds from sale of common stock             $ 9,100,000   $ 99,999     $ 2,373,561   $ 2,473,560  
Warrant liability                         $ 2,152,188 245,341  
Transaction costs                 $ 0     $ 0      
Stock compensation expense                         $ 3,089,303 2,319,427  
Deemed dividend on warrant modification                           $ (450,578)  
Warrants exercised, shares                 394,501            
Cashless exercise at fair market value per share                 $ 9            
Issuance of common shares upon cashless exercise of warrants, shares                 315,601            
Stock options outstanding                         7,750,152 6,545,628  
Fair value assumptions, contractual term                         7 years    
Exercise price percentage                         110.00%    
Percentage of shares granted                         10.00%    
Warrants exercise price, per share               $ 6.25              
Warrants and rights exercisable period               Jan. 23, 2023              
Class of warrant or right date from which warrants or rights expire               Jul. 27, 2027              
Warrants                         $ 2,152,188 $ 245,341  
Gain on remeasurement of warrant liability                         $ (205,130) $ (98,394)  
Warrants issued                         2,853,293    
Black-Sholes Method                              
Subsidiary or Equity Method Investee [Line Items]                              
Risk free interest rate             2.82%                
Volatility rate             77.50%                
Fair value assumptions, contractual term             5 years                
Warrants             $ 343,735           $ 40,211    
Gain on remeasurement of warrant liability                         $ (205,130)    
Maximum                              
Subsidiary or Equity Method Investee [Line Items]                              
Fair value assumptions, contractual term                         10 years    
Warrants to purchase common stock               100,000              
2018 Stock Option Plan                              
Subsidiary or Equity Method Investee [Line Items]                              
Stock options outstanding                         1,924,500    
Amended and Restated 2020 Equity Incentive Plan                              
Subsidiary or Equity Method Investee [Line Items]                              
Common stock reserved for issuance                         0    
Stock options outstanding                         3,852,187    
2021 Equity Incentive Plan                              
Subsidiary or Equity Method Investee [Line Items]                              
Common stock reserved for issuance               1,909,518         2,023,132 1,956,993  
Percentage of increase in stock outstanding fully diluted         10.00%                    
Stock options outstanding                         1,973,465    
Alumni Capital LP                              
Subsidiary or Equity Method Investee [Line Items]                              
Risk free interest rate       3.93%                      
Volatility rate       90.00%                      
Fair value assumptions, contractual term       3 years 10 months 13 days                      
Warrants exercise price, per share       $ 2.09                      
Warrant fee paid in cash       $ 13,750                      
Warrant shares vested     131,578                        
Warrants and rights exercisable period       Nov. 10, 2023                      
Class of warrant or right date from which warrants or rights expire       Nov. 10, 2027                      
Warrants       $ 84,251                      
Alumni Capital LP | Maximum                              
Subsidiary or Equity Method Investee [Line Items]                              
Warrants to purchase common stock       239,234                      
IPO                              
Subsidiary or Equity Method Investee [Line Items]                              
Common stock, shares issued               219,872              
Number of common stock sold           2,555,500   2,000,000              
Sale of common stock, price per share           $ 2.25                  
Common stock per share               $ 5       $ 5      
Gross proceeds from common stock               $ 10,000,000              
Gross proceeds from sale of common stock           $ 4,200,000                  
Number of warrants exercised               20,520              
Warrants exercise price, per share               $ 5              
Follow-on Offering                              
Subsidiary or Equity Method Investee [Line Items]                              
Risk free interest rate               4.09%              
Volatility rate               86.30%              
Fair value assumptions, contractual term                            
Warrants exercise price, per share               $ 2.81              
Warrants and rights exercisable period               Oct. 24, 2023              
Class of warrant or right date from which warrants or rights expire               Apr. 24, 2028              
Class of warrant or right additional purchase aggregate of common stock               241,109              
Follow-on Offering | Maximum                              
Subsidiary or Equity Method Investee [Line Items]                              
Warrants to purchase common stock               127,775              
Follow-on Offering | ThinkEquity LLC                              
Subsidiary or Equity Method Investee [Line Items]                              
Number of common stock sold           2,555,500                  
Common stock per share           $ 2.25                  
Gross proceeds from common stock           $ 4,156,859                  
At-the-Market Equity Offering                              
Subsidiary or Equity Method Investee [Line Items]                              
Common stock, par value                             $ 0.0001
Number of common stock sold                     758,388        
Gross proceeds from common stock                     $ 1,238,688        
Warrant liability                     $ 84,251        
Registered Direct Offering                              
Subsidiary or Equity Method Investee [Line Items]                              
Common stock, par value $ 0.0001                            
Gross proceeds from common stock $ 3,400,000                            
Warrant liability $ 2,000,000                            
Risk free interest rate   3.84%                     3.85%    
Volatility rate   90.00%                     90.00%    
Fair value assumptions, contractual term   4 years 10 months 17 days                     5 years 4 months 17 days    
Warrants to purchase common stock   169,697                          
Warrants exercise price, per share   $ 2.06                     $ 1.86    
Warrants and rights exercisable period   Nov. 15, 2023                     Nov. 15, 2023    
Class of warrant or right date from which warrants or rights expire   Nov. 15, 2028                     May 17, 2029    
Warrants   $ 123,811                     $ 1,903,915    
Registered Direct Offering | Maximum                              
Subsidiary or Equity Method Investee [Line Items]                              
Warrants to purchase common stock                         2,424,243    
Overallotment Option                              
Subsidiary or Equity Method Investee [Line Items]                              
Number of common stock sold             300,000                
Common stock per share             $ 5                
Gross proceeds from common stock             $ 1,500,000                
Overallotment Option | Maximum                              
Subsidiary or Equity Method Investee [Line Items]                              
Class of warrant or right additional purchase aggregate of common stock             15,000                
Common Stock                              
Subsidiary or Equity Method Investee [Line Items]                              
Number of common stock sold                 11,111     263,729      
Sale of common stock, price per share                 $ 9     $ 9      
Issuance of restricted common shares, Shares                         291,469    
Issuance of common shares upon exercise of warrants, Shares                 153,000 61,111       529,712  
Proceeds from issuance of common stock upon exercise of warrants                 $ 275,400 $ 110,000          
Common Stock | IPO                              
Subsidiary or Equity Method Investee [Line Items]                              
Number of common stock sold                           2,300,000  
Common Stock | Follow-on Offering                              
Subsidiary or Equity Method Investee [Line Items]                              
Number of common stock sold                         2,555,500    
Common Stock | At-the-Market Equity Offering                              
Subsidiary or Equity Method Investee [Line Items]                              
Number of common stock sold                         758,388    
Common Stock | At-the-Market Equity Offering | Maximum                              
Subsidiary or Equity Method Investee [Line Items]                              
Aggregate offering price                             $ 7,000,000
Common Stock | Registered Direct Offering                              
Subsidiary or Equity Method Investee [Line Items]                              
Number of common stock sold 2,424,243                            
Founder                              
Subsidiary or Equity Method Investee [Line Items]                              
Stock compensation expense                           $ 52,500  
Restricted Stock Awards                              
Subsidiary or Equity Method Investee [Line Items]                              
Stock compensation expense                         $ 731,661    
Shares granted                         291,469    
Unvested shares                         0    
Restricted Stock Awards | Founder                              
Subsidiary or Equity Method Investee [Line Items]                              
Shares granted                           29,168  
MAIA Stock Warrants                              
Subsidiary or Equity Method Investee [Line Items]                              
Warrant modification, value                   $ 144,497          
Deemed dividend on warrant modification                           $ 450,578  
Stock Options                              
Subsidiary or Equity Method Investee [Line Items]                              
Weighted-average grant date fair value                         $ 2.55 $ 3.75  
Unrecognized compensation                         $ 1,790,683    
Unrecognized compensation expense, recognized period                         2 years 11 months 23 days    
Stock Options | Maximum                              
Subsidiary or Equity Method Investee [Line Items]                              
Fair value assumptions, contractual term                         6 years 3 months 6 years 3 months  
Stock Options | Minimum                              
Subsidiary or Equity Method Investee [Line Items]                              
Fair value assumptions, contractual term                         5 years 5 years